Investview, INC 8-K filings

Investview, Inc. announced the appointment of Robert Verdun, an experienced entrepreneur and corporate director, to its Board of Directors, effective January 28, 2026.

Investview's iGenius unit faces a $4 million fine and cease-and-desist order from Polish regulators over alleged pyramid scheme violations, which the company plans to appeal.

Investview, Inc. terminated its agreement to repurchase 121 million shares from non-affiliate shareholders after the sellers failed to deliver the shares by the extended closing date.

Investview, Inc. has initiated legal action against Total Protection Plus (TPP) to compel them to honor commitments made to Investview's customers under the TPP Program related to the Apex and ndau programs.

Investview, Inc. has authorized a stock repurchase program of up to $1 million, citing undervaluation after a recent SEC settlement.

Investview, Inc. amended its Securities Purchase Agreement with DBR Capital, extending the availability of loans and reducing interest rates on potential future borrowings.

Investview, Inc. has reached a settlement with the SEC, resolving an inquiry related to a past program involving unregistered investment contracts and agreeing to pay a $375,000 penalty.

Investview, Inc. has announced the repurchase of 121 million shares and the acquisition of Renu Laboratories, a health and wellness product manufacturer.

Investview, Inc. has received notice from the OTC Markets Group that its share price has fallen below the minimum threshold for continued listing on the OTCQB market, triggering a cure period.

Investview Inc. reports the resignation of Myles P. Gill as Director of Operations, effective August 14, 2024.

Investview, Inc. has acquired Opencash Securities LLC, an early-stage broker-dealer, marking its entry into the retail brokerage market.

Investview, Inc. has repurchased 472,374,710 shares of its common stock from its co-founders and their affiliates, reducing its outstanding shares by 20.24%.